Cargando…

Utilizing the MEST score for prognostic staging in IgA nephropathy

BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Haaskjold, Yngvar Lunde, Bjørneklett, Rune, Bostad, Leif, Bostad, Lars Sigurd, Lura, Njål Gjærde, Knoop, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753851/
https://www.ncbi.nlm.nih.gov/pubmed/35016634
http://dx.doi.org/10.1186/s12882-021-02653-y
_version_ 1784632156482437120
author Haaskjold, Yngvar Lunde
Bjørneklett, Rune
Bostad, Leif
Bostad, Lars Sigurd
Lura, Njål Gjærde
Knoop, Thomas
author_facet Haaskjold, Yngvar Lunde
Bjørneklett, Rune
Bostad, Leif
Bostad, Lars Sigurd
Lura, Njål Gjærde
Knoop, Thomas
author_sort Haaskjold, Yngvar Lunde
collection PubMed
description BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients with biopsy-proven primary IgAN were included. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford classification. The study endpoint was end-stage renal disease (ESRD). Patients were subclassified into three risk models based on histologic features (Model A), a composite score calculated from the adjusted hazard ratio values (Model B), and on quartiles (Model C). RESULTS: The mean follow-up time was 16.5 years (range 0.2–28.1). In total, 61 (20%) patients reached ESRD during the study period. Univariate analysis of M, E, S, T and C lesions demonstrated that all types were associated with an increased risk of ESRD; however, a multivariate analysis revealed that only S, T and C lesions were associated with poor outcomes. Statistical analysis of 15-year data demonstrated that Models A and B were as predictive as the MEST score, with an area-under-the-curve at 0.85. The Harrel c index values were 0.81 and 0.80 for the MEST score and Models A and B, respectively. In the present cohort, adding C lesions to the MEST score did not improve the models prognostic value. CONCLUSIONS: Patients can be divided into risk classes based on their MEST scores. Histopathologic data provide valuable prognostic information at the time of diagnosis. Model B was the most suitable for clinical practice because it was the most user-friendly. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02653-y.
format Online
Article
Text
id pubmed-8753851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87538512022-01-12 Utilizing the MEST score for prognostic staging in IgA nephropathy Haaskjold, Yngvar Lunde Bjørneklett, Rune Bostad, Leif Bostad, Lars Sigurd Lura, Njål Gjærde Knoop, Thomas BMC Nephrol Research BACKGROUND: The Oxford classification/MEST score is an established histopathologic scoring system for patients with IgA nephropathy (IgAN). The objective of this study was to derive a prognostic model for IgAN based on the MEST score and histopathologic features. METHODS: A total of 306 patients with biopsy-proven primary IgAN were included. Histopathologic samples were retrieved from the Norwegian Kidney Biopsy Registry and reclassified according to the Oxford classification. The study endpoint was end-stage renal disease (ESRD). Patients were subclassified into three risk models based on histologic features (Model A), a composite score calculated from the adjusted hazard ratio values (Model B), and on quartiles (Model C). RESULTS: The mean follow-up time was 16.5 years (range 0.2–28.1). In total, 61 (20%) patients reached ESRD during the study period. Univariate analysis of M, E, S, T and C lesions demonstrated that all types were associated with an increased risk of ESRD; however, a multivariate analysis revealed that only S, T and C lesions were associated with poor outcomes. Statistical analysis of 15-year data demonstrated that Models A and B were as predictive as the MEST score, with an area-under-the-curve at 0.85. The Harrel c index values were 0.81 and 0.80 for the MEST score and Models A and B, respectively. In the present cohort, adding C lesions to the MEST score did not improve the models prognostic value. CONCLUSIONS: Patients can be divided into risk classes based on their MEST scores. Histopathologic data provide valuable prognostic information at the time of diagnosis. Model B was the most suitable for clinical practice because it was the most user-friendly. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02653-y. BioMed Central 2022-01-11 /pmc/articles/PMC8753851/ /pubmed/35016634 http://dx.doi.org/10.1186/s12882-021-02653-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Haaskjold, Yngvar Lunde
Bjørneklett, Rune
Bostad, Leif
Bostad, Lars Sigurd
Lura, Njål Gjærde
Knoop, Thomas
Utilizing the MEST score for prognostic staging in IgA nephropathy
title Utilizing the MEST score for prognostic staging in IgA nephropathy
title_full Utilizing the MEST score for prognostic staging in IgA nephropathy
title_fullStr Utilizing the MEST score for prognostic staging in IgA nephropathy
title_full_unstemmed Utilizing the MEST score for prognostic staging in IgA nephropathy
title_short Utilizing the MEST score for prognostic staging in IgA nephropathy
title_sort utilizing the mest score for prognostic staging in iga nephropathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753851/
https://www.ncbi.nlm.nih.gov/pubmed/35016634
http://dx.doi.org/10.1186/s12882-021-02653-y
work_keys_str_mv AT haaskjoldyngvarlunde utilizingthemestscoreforprognosticstaginginiganephropathy
AT bjørneklettrune utilizingthemestscoreforprognosticstaginginiganephropathy
AT bostadleif utilizingthemestscoreforprognosticstaginginiganephropathy
AT bostadlarssigurd utilizingthemestscoreforprognosticstaginginiganephropathy
AT luranjalgjærde utilizingthemestscoreforprognosticstaginginiganephropathy
AT knoopthomas utilizingthemestscoreforprognosticstaginginiganephropathy